Palmitoyl Pentapeptide-4

Origin and Structure

Palmitoyl pentapeptide-4, known commercially as Matrixyl and chemically as Pal-KTTKS, is a lipopeptide formed by attaching a 16-carbon palmitic acid chain to the N-terminus of the pentapeptide sequence lysine-threonine-threonine-lysine-serine (KTTKS). The KTTKS sequence itself is a fragment of the C-terminal propeptide of type I procollagen — a piece that is normally cleaved off during collagen maturation and acts as a feedback signal to fibroblasts.

The compound was developed by Procter & Gamble researchers in the early 1990s and commercialized by Sederma (a specialty peptide supplier now part of Croda) under the Matrixyl trade name. The palmitoyl modification was added to solve a fundamental formulation problem: the native KTTKS pentapeptide is strongly hydrophilic and does not penetrate the stratum corneum at useful rates. Covalent attachment of palmitic acid converts the peptide into an amphipathic molecule that partitions into the lipid lamellae of the stratum corneum and reaches the viable epidermis and upper dermis.

Mechanism of Action

Palmitoyl pentapeptide-4 functions as a matrikine mimetic. The native KTTKS fragment acts as a negative-feedback signal in wound healing — when fibroblasts encounter released procollagen propeptide, they interpret it as evidence that collagen synthesis is already underway and modulate matrix production accordingly. Exogenous Pal-KTTKS appears to exploit this signaling pathway to stimulate:

• Collagen I, III, and IV synthesis. Dermal fibroblast cultures treated with Pal-KTTKS produce more of each at the transcriptional and protein level.
• Fibronectin production. The glycoprotein scaffold on which new collagen deposits.
• Glycosaminoglycan output. Hyaluronic acid and related ground-substance components.

The effect is slow and cumulative — consistent with the biology of dermal matrix remodeling rather than with acute physiological responses.

Clinical Evidence

Palmitoyl pentapeptide-4 has a stronger cosmetic clinical record than most peptides in the skin-care category. A frequently cited 12-week split-face double-blind trial by Robinson and colleagues (published 2005) reported measurable reductions in wrinkle depth and improvements in skin smoothness on the treated side at concentrations of 3 parts per million Pal-KTTKS in a standard cream base. Subsequent independent formulation studies have broadly replicated the direction of effect, though absolute magnitudes vary with vehicle and protocol.

Effect sizes are small in absolute terms. Pal-KTTKS does not produce the kind of visible change a neuromodulator injection would; it delivers gradual improvements in fine-line depth and dermal texture over months of consistent use.

Formulation Considerations

Pal-KTTKS is typically formulated at 3 to 5 parts per million (0.0003 to 0.0005 percent) in finished products — a vanishingly low concentration that nevertheless represents the effective range established in the development work. Higher concentrations do not appear to produce proportionally larger effects, which is consistent with receptor-saturation pharmacology.

The compound is often combined with palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 in a formulation branded Matrixyl 3000, which is marketed as having synergistic effects across multiple matrix-signaling pathways. The Matrixyl synthe'6 variant adds a lysine-based peptide targeting a different set of matrix components.

Safety and Regulatory Status

Palmitoyl pentapeptide-4 is used as a cosmetic ingredient globally with a long and reassuring safety record. Adverse events are limited to rare reports of mild irritation or contact sensitivity. The Cosmetic Ingredient Review panel has assessed the palmitoyl oligopeptide class as safe for use as cosmetic ingredients at typical formulation levels. The compound is not a drug by FDA definition — cosmetic claims center on appearance rather than structural or functional change to the skin — which is the regulatory posture under which nearly all Matrixyl-containing products are marketed.

Bottom Line

Palmitoyl pentapeptide-4 is one of the better-validated cosmetic peptides, with real (if modest) clinical support and a mechanism that makes biological sense. Anyone evaluating "collagen-stimulating" skincare claims should compare the evidence on Pal-KTTKS against less well-supported peptide ingredients in the category. See our Matrixyl reference for the commercial ingredient overview and copper peptide complex for the adjacent category.